Xinling Wang

1.5k total citations
17 papers, 360 citations indexed

About

Xinling Wang is a scholar working on Infectious Diseases, Animal Science and Zoology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Xinling Wang has authored 17 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 5 papers in Animal Science and Zoology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Xinling Wang's work include SARS-CoV-2 and COVID-19 Research (11 papers), Viral gastroenteritis research and epidemiology (5 papers) and COVID-19 Clinical Research Studies (5 papers). Xinling Wang is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (11 papers), Viral gastroenteritis research and epidemiology (5 papers) and COVID-19 Clinical Research Studies (5 papers). Xinling Wang collaborates with scholars based in China, United States and South Korea. Xinling Wang's co-authors include Shibo Jiang, Lu Lu, Shuai Xia, Wei Xu, Qian Wang, Zezhong Liu, Jie Zhou, Youhua Xie, Di Qu and Zhenghong Yuan and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and International Journal of Molecular Sciences.

In The Last Decade

Xinling Wang

16 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xinling Wang China 12 268 79 68 64 38 17 360
Mona Fani Iran 13 239 0.9× 232 2.9× 55 0.8× 30 0.5× 63 1.7× 26 512
Agnieszka Dąbrowska Poland 11 230 0.9× 96 1.2× 37 0.5× 27 0.4× 46 1.2× 19 403
Boxuan Huang China 8 157 0.6× 191 2.4× 25 0.4× 20 0.3× 36 0.9× 10 375
Srijan Chatterjee India 12 237 0.9× 169 2.1× 47 0.7× 27 0.4× 39 1.0× 27 483
Prabin Baral United States 9 146 0.5× 136 1.7× 31 0.5× 11 0.2× 26 0.7× 17 296
Joshua M. Thiede United States 8 284 1.1× 193 2.4× 51 0.8× 30 0.5× 130 3.4× 13 441
Christian S. Stevens United States 5 262 1.0× 92 1.2× 93 1.4× 42 0.7× 31 0.8× 11 339
Ruiying Han China 4 145 0.5× 96 1.2× 26 0.4× 22 0.3× 16 0.4× 10 282
Yinzhu Luo China 8 102 0.4× 94 1.2× 23 0.3× 17 0.3× 44 1.2× 16 299
Yeu Khai Choong Singapore 9 95 0.4× 141 1.8× 85 1.3× 8 0.1× 18 0.5× 18 328

Countries citing papers authored by Xinling Wang

Since Specialization
Citations

This map shows the geographic impact of Xinling Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinling Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinling Wang more than expected).

Fields of papers citing papers by Xinling Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinling Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinling Wang. The network helps show where Xinling Wang may publish in the future.

Co-authorship network of co-authors of Xinling Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Xinling Wang. A scholar is included among the top collaborators of Xinling Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinling Wang. Xinling Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Zhang, Han, Yan Zhang, Ziyue Li, et al.. (2025). Screening and discovery of an antiviral candidate inhibiting the SARS-CoV-2 envelope (2-E) channel. Current Research in Microbial Sciences. 9. 100409–100409. 1 indexed citations
2.
Wang, Xinling, Qianying Liu, Wei Xu, et al.. (2025). Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. Cell. 188(5). 1297–1314.e24. 11 indexed citations
3.
Wang, Lingling, Xinling Wang, Kaile Wang, et al.. (2025). New Chaetoglobosins with Fungicidal Activity from Chaetomium sp. UJN-EF006 Endophytic in Vaccinium bracteatum. Journal of Fungi. 11(7). 511–511. 1 indexed citations
4.
Wang, Xinling, Lu Lu, & Shibo Jiang. (2024). SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences. Trends in Immunology. 45(2). 81–84. 24 indexed citations
5.
Liu, Zezhong, Jie Zhou, Xinling Wang, et al.. (2023). A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. Proceedings of the National Academy of Sciences. 120(11). e2221713120–e2221713120. 16 indexed citations
6.
Wang, Xinling, Lu Lu, & Shibo Jiang. (2023). SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread. Signal Transduction and Targeted Therapy. 8(1). 439–439. 13 indexed citations
7.
Wang, Xinling, Zezhong Liu, Yun Zhu, et al.. (2023). An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen. Emerging Microbes & Infections. 12(2). 2244084–2244084. 11 indexed citations
9.
Xue, Songyi, Xinling Wang, Lei Wang, et al.. (2022). A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein. Cell Discovery. 8(1). 88–88. 18 indexed citations
10.
Wang, Xinling, Zezhong Liu, Lu Lu, & Shibo Jiang. (2022). The putative mechanism of lymphopenia in COVID-19 patients. Journal of Molecular Cell Biology. 14(5). 7 indexed citations
11.
Wang, Xinling, Shuai Xia, Yun Zhu, Lu Lu, & Shibo Jiang. (2021). Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein & Cell. 12(2). 84–88. 32 indexed citations
12.
Liu, Zezhong, Wei Xu, Shuai Xia, et al.. (2020). RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy. 5(1). 282–282. 140 indexed citations
13.
Liu, Zezhong, Shuai Xia, Xinling Wang, et al.. (2020). Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. ACS Infectious Diseases. 6(5). 882–890. 13 indexed citations
14.
Wang, Xinling, Shuai Xia, Qian Wang, et al.. (2020). Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. International Journal of Molecular Sciences. 21(11). 3843–3843. 36 indexed citations
15.
Luo, Li, et al.. (2017). Intervention of the Nuss Procedure on the Mental Health of Pectus Excavatum Patients. Annals of Thoracic and Cardiovascular Surgery. 23(4). 175–180. 11 indexed citations
16.
Wang, Yanhai, et al.. (2017). Inactivation of Human Rhinovirus due to Heat, UV Irradiation and Chemical Disinfectants. Journal of Antivirals & Antiretrovirals. 9(4).
17.
Zhang, Jian, et al.. (2015). Cellular response of chondrocytes to magnesium alloys for orthopedic applications. International Journal of Molecular Medicine. 36(1). 73–82. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026